Sware

About Sware

Sware provides GxP validation services aimed at helping life sciences companies escape validation debt. Their mission is to transform GxP compliance by automating validation processes, reducing costs, minimizing compliance risks, and enabling organizations to focus on high-value work through AI-powered solutions like Res_Q.

Products & Services

Res_Q:An AI-powered platform that automates GxP validation, analyzes equipment data, delivers real-time insights, and simplifies change management, reducing validation time by up to 80%.

GxPNext:A solution for GxP compliance and validation, though specific details are not provided in the content.

Specialties

GxP Validation AI-Powered Compliance Validation Automation Change Management

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 6000000 MR: - FA: $6 million FAN: 6000000	D: 2024-06-06 FD: 2024-06-06	4 investors

Series B Latest

2024-06-06

$6.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Ellen Reilly

Chief Executive Officer

B

Bryan Ennis

Chief Quality Officer & Co-Founder

C

Colleen Burns

Chief Marketing Officer

S

Sara Blakely

T

Theresa Pauzer

Chief People Officer

B

Brad Hainer

Head of Revenue

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

Sware Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised